.svg){kind=small}
Latest articles
No items found.
Follow Us
Treatment options for people with intermediate to advanced dry age-related macular degeneration (AMD) have historically been limited, with most approaches focused on slowing disease progression rather than improving visual function.
The i-SIGHT2 clinical study is currently enrolling participants across the United States, United Kingdom, Australia, and New Zealand to evaluate the safety and effectiveness of a non-invasive, in-clinic bioelectric therapy.
This approach is designed to target the electrophysiologic dysfunction of the retina by restoring the retinal pigment epithelium’s electrical potential, with the goal of improving photoreceptor performance and visual acuity.
.svg){kind=icon}
Patients that receive i‑Lumen AMD therapy may see an improvement in their visual acuity (detailed central vision), and/or slowing of the disease progression.
.svg){kind=icon}
Eligible participants that are enrolled in the study will attend monthly visits for monitoring by qualified healthcare professionals, and ongoing therapy over a two-year period.
Study participants will be reimbursed for travel expenses associated with the research project.
.svg){kind=icon}
There is no guarantee of benefits. The study will contribute to continued development of therapy options.
.png)
-update.svg)
